Loading
Immune Checkpoint Inhibitor (icis) / Drug Induced Liver Injury · Journal article
Future Science Oa · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report describing severe drug-induced liver injury in a 51-year-old male with small-cell lung cancer nine cycles after starting adebrelimab combined with etoposide/carboplatin. The updated RUCAM causality assessment tool yielded a score of 8, indicating a highly probable causal relationship, and liver function normalized with corticosteroid and supportive treatment.
Single case report. One 51-year-old male with small-cell lung cancer receiving etoposide/carboplatin combined with adebrelimab; baseline liver function normal; no hepatobiliary disease history. Intervention: Adebrelimab combined with etoposide/carboplatin (9 cycles over 5 months); followed by methylprednisolone 1 mg/kg/d. n = 1.
Severe jaundice developed four days after final etoposide/carboplatin/adebrelimab dose at 5 months (nine cycles of therapy) Updated RUCAM score was 8, indicating highly probable causality between regimen and liver injury Simplified AIH score <6 ruled out autoimmune hepatitis as alternative etiology
Single case report; incidence, risk factors, or population prevalence of adebrelimab-related hepatotoxicity not quantified
This case demonstrates the practical utility of the updated RUCAM score in distinguishing drug-induced liver injury from autoimmune causes in immune checkpoint inhibitor recipients. Clinicians should consider adebrelimab as a potential hepatotoxic agent, particularly with delayed onset beyond label timeframe, and recognize corticosteroid responsiveness in management.
Single case report of adebrelimab-induced liver injury with RUCAM causality assessment; demonstrates clinical utility of diagnostic tool but provides no comparative efficacy data or population estimates.
As stated by the source record.
Quoted from the source exactly as published.
This case demonstrates the practical utility of the updated RUCAM score in distinguishing drug-induced liver injury from autoimmune causes in immune checkpoint inhibitor recipients. Clinicians should consider adebrelimab as a potential hepatotoxic agent, particularly with delayed onset beyond label timeframe, and recognize corticosteroid responsiveness in management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Aim. To report a case of Adebrelimab-related liver injury and emphasize the role of the updated RUCAM in causality assessment for suspected immune checkpoint inhibitor-induced hepatotoxicity.Observation. A 51-year-old male with small-cell lung cancer developed severe jaundice four days after his last dose of etoposide/carboplatin combined with adebrelimab, occurring after nine cycles of therapy (at 5 months) and later than the onset time described in the drug label. Baseline liver function was normal, and there was no history of hepatobiliary disease. Physical examination revealed jaundice and scleral icterus. The updated RUCAM score was 8, indicating a highly probable relationship between the regimen and liver injury, while the simplified AIH score (<6) ruled out autoimmune hepatitis. The patient's liver enzymes and bilirubin normalized, and clinical symptoms improved following treatment with low-dose methylprednisolone (1 mg/kg/d) and other supportive measures.Conclusion. This case highlights the value of applying the updated RUCAM to reliably distinguish drug-induced liver injury from other etiologies in immune checkpoint inhibitor recipients, thereby guiding appropriate clinical management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.